NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an update on its two FDA-approved products. Phase IV study of ...

Eyenovia licensed clobetasol propionate ophthalmic suspension 0.05%, which leverages APNT technology, from Formosa in August 2023, and clobetasol was subsequently approved by the U.S. Food and ...

Eyenovia licensed clobetasol propionate ophthalmic suspension 0.05%, which leverages APNT technology, from Formosa in August 2023, and clobetasol was subsequently approved by the U.S. Food and ...

Eyenovia licensed clobetasol propionate ophthalmic suspension 0.05%, which leverages APNT technology, from Formosa in August 2023, and clobetasol was subsequently approved by the U.S. Food and ...

Eyenovia licensed clobetasol propionate ophthalmic suspension 0.05%, which leverages APNT technology, from Formosa in August 2023, and clobetasol was subsequently approved by the U.S. Food and Drug ...

Neither drugmaker listed a reason. Clobetasol propionate cream: Fougera, a Sandoz company, discontinued nine presentations of its skin condition medication. A reason was not provided ...

A clinical diagnosis was made of psoriasis and he was prescribed clobetasol propionate ointment with salicylic acid 6% in petrolatum that should be applied in the evening to his elbows and knees ...

clobetasol propionate, and dexamethasone. The patient did not react to tixocortol-21-pivalate (Fig 2), a screening agent for allergy to group A corticosteroids, which include prednisone ...

Eyenovia licensed clobetasol propionate ophthalmic suspension 0.05%, which leverages APNT technology, from Formosa in August 2023, and clobetasol was subsequently approved by the U.S. Food and Drug ...

Eyenovia licensed clobetasol propionate ophthalmic suspension 0.05%, which leverages APNT technology, from Formosa in August 2023, and clobetasol was subsequently approved by the U.S. Food and Drug ...